The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Madan JagasiaThe GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Madan H. Jagasia, Vanderbilt University Medical Center, Nashville, US, was based on the question: Is sustained treatment with KD025 required for chronic graft-versus-host disease control?
Madan Jagasia discusses the mechanism of action of KD025 treatment. He also shares his data of the 24 months follow-up of patients treated with this molecule and explains a subset of patients may benefit from longer exposure of treatment. He concludes by explaining there is a pivotal trial that is exploring the effects of prolonged exposure to KD025 in the cGvHD setting and will hopefully provide more answers.
Is sustained treatment with KD025 required for cGvHD control?